Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

I Leader della Finanza

Ultime notizieSocietÓMercatiEconomia & ForexMaterie PrimeTassiLeader della FinanzaPro. della FinanzaAgendaSettori 
HomeTutte le notizieLe notizie pi¨ letteBiografie dei Leader della finanza
Portrait de Fred Ehrenkranz Cohen
EtÓ : 63
Patrimonio pubblico : 13 739 875 USD
Principali societÓ : Intellia Therapeutics, Inc. - Progyny, Inc. - CareDx, Inc - UroGen Pharma Ltd.
Riassunto 
Founder of 5 different companies, among them: Kyverna Therapeutics, Inc., TPG Biotechnology Partners LP and Cell Design Labs, Inc. Fred E. Cohen is an entrepreneur and presently occupies the position of Senior Managing Director at VV Manager LLC (which he founded in 2017), Chairman for Cell Design Labs, Inc. (which he founded in 2016) and Advisor at CHV Capital, Inc.

He is also Member of American Academy of Arts & Sciences, Member of Institute of Medicine, Member of Association of American Physicians, Member of American Society for Clinical Investigation, Member of National Academy of Medicine and Managing Director & Partner at Tarrant Capital IP LLC and on the board of 14 other companies.

In his past career Fred E. Cohen occupied the position of Director at Rapid Micro Biosystems, Inc., Senior Director-Business Development at Kosan Biosciences, Inc., Managing Director at The Plastics Group, Inc., Managing Director & Partner at TPG Biotechnology Partners LP (he founded the company in 2001), Senior Managing Partner at Vida Ventures LLC (he founded the company in 2017), Partner at TPG Capital LLC and Professor at The University of California, San Francisco.

Dr. Cohen received an undergraduate degree from Yale University, a doctorate from the University of Oxford and a doctorate from Stanford University.


Posti e reponsabilitÓ di Fred Ehrenkranz Cohen 
NomeTitolo Da
Intellia Therapeutics, Inc.
(Biotecnologia)
Independent Director 2019
Progyny, Inc.
(Gestione sanitÓ)
Independent Director 2015
CareDx, Inc
(Biotecnologia)
Independent Director 2003
UroGen Pharma Ltd.
(Biotecnologia)
Independent Director 2017
Cell Design Labs, Inc. Chairman 2016
Tarrant Capital IP LLC Managing Director & Partner 2013
Quintiles Transnational Corp. Director -
Acumen, Inc. Director -
UCSF Foundation Director 1987
Novotech (Australia) Pty Ltd. Director -
Matrix Pharmaceuticals, Inc. Director -
Autistica Trustee -
Kyverna Therapeutics, Inc. Director -
Acrostar Pharmaservices Corp. Director 2017
Novotech Aus Holdco Pty Ltd. Director 2018
Novotech Health Holdings Ltd. Non-Executive Director 2020
American Academy of Arts & Sciences Member 2008
Institute of Medicine Member 2004
Association of American Physicians Member 1995
American Society for Clinical Investigation Member 1990
National Academy of Medicine Member -
VV Manager LLC Co-Founder and Senior Managing Director 2017


Participazioni di Fred Ehrenkranz Cohen 
NomeAzioni%Valorizzazione
CareDx, Inc (CDNA)
(Biotecnologia)
107 0200,20%7 842 426 USD
Intellia Therapeutics, Inc. (NTLA)
(Biotecnologia)
32 0940,044%5 152 050 USD
Veracyte, Inc. (VCYT)
(Biotecnologia)
10 0000,014%481 100 USD
UroGen Pharma Ltd. (URGN)
(Biotecnologia)
15 0000,067%264 300 USD
Progyny, Inc. (PGNY)
(Gestione sanitÓ)
00,0000%0 USD


Fred Ehrenkranz Cohen: network personale 
Le notizie pi¨ lette 
15/09BRAD SMITH: Microsoft annuncia il riacquisto di azioni fino a 60 miliardi di dollari e aumenta il dividendo
MR
13/09MARTIN SORRELL: S4 Capital di Sorrell alza le prospettive di profitto al 40%
MR
14/09STEPHEN SCHERR: Goldman Sachs nomina Coleman come nuovo CFO, sostituendo Scherr
MR
08/09MICHAEL O'LEARY: Ryanair, aeroporti britannici in difficoltà a Natale - O'Leary
RE
09/09FRANCESCO GAETANO CALTAGIRONE: Generali, Caltagirone arrotonda quota a 6,1%
RE
17/09LEONARDO DEL VECCHIO: Generali, Caltagirone e Del Vecchio cercano alleati, non vogliono Opa
RE
15/09FRANCESCO GAETANO CALTAGIRONE: Generali, Caltagirone aumenta quota di ulteriore 0,11%, sale sopra 6%
RE
14/09VINCENT BOLLORÉ: Bolloré avrà quota Universal da 5,9 mld euro dopo quotazione
RE
Pi¨ notizie


© 2021 People and Ownership :   
Fred Ehrenkranz Cohen : connessioni